Press Releases Roivant Sciences Ltd.

Equities

ROIV

BMG762791017

Delayed Nasdaq Other stock markets 03:46:49 2024-05-17 pm EDT			5-day change	1st Jan Change
11.23 ^USD	-1.58%		+0.85%	-0.04%

Apr. 05	Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	MT
Apr. 04	Moderna Suffers Setback in Lawsuit by Arbutus	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024	May. 16	GL
Tesla, UnitedHealth Group fall; Roivant, Valero rise, Tuesday, 4/2/2024	Apr. 02	AQ
Roivant Sciences : NIU Phase 2 Topline Results	Apr. 02	PU
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million	Apr. 02	GL
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update	Feb. 13	GL
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update	Feb. 13	AQ
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024	Jan. 30	GL
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024	Jan. 30	AQ
Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors	Jan. 19	AQ
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease	Dec. 20	GL
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease	Dec. 14	GL
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease	Dec. 14	AQ
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential	Nov. 28	GL
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential	Nov. 28	AQ
Cerence, Roivant Sciences fall; Xenon Pharmaceuticals, Shopify rise, Monday, 11/27/2023	Nov. 27	AQ
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus	Nov. 27	GL
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus	Nov. 27	AQ
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update	Nov. 13	GL
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update	Nov. 13	AQ
Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors	Nov. 10	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Roivant Sciences Ltd.

Equities

ROIV

BMG762791017

Press Releases

Filters